Related Experiment Videos
Leukotriene-receptor antagonists. Role in asthma management
1Department of Family and Community Medicine University of Toronto.
Summary
Leukotriene-receptor antagonists (LTRAs) effectively manage asthma by improving lung function and reducing symptoms. These oral medications offer a safe alternative or adjunct therapy to inhaled corticosteroids for better asthma control.
Area of Science:
- Pharmacology
- Respiratory Medicine
- Immunology
Background:
- Leukotrienes play a significant role in asthma pathophysiology, contributing to airway inflammation.
- Asthma management traditionally relies on inhaled corticosteroids.
Purpose of the Study:
- To evaluate the efficacy of leukotriene-receptor antagonists (LTRAs) in asthma management.
- To explore the role of LTRAs as an alternative or adjunctive therapy.
Main Methods:
- Analysis of data primarily from randomized, double-blind, controlled trials.
- Assessment of LTRAs' impact on asthma control end points and lung function.
Main Results:
- LTRAs improve asthma control in clinical models and chronic asthma.
- Administration of LTRAs reduces symptoms, rescue medication use, and eosinophil levels.
- LTRAs can facilitate a reduction in inhaled corticosteroid dosage and are well-tolerated.
Conclusions:
- Leukotriene-receptor antagonists represent a novel class of asthma medications.
- LTRAs are recommended for ASA-sensitive asthma or as add-on therapy for incomplete control with inhaled steroids.
- LTRAs offer a safe, oral option to enhance asthma management and potentially reduce corticosteroid dependence.